Category: Zacks Small Cap Research
Few things matter more to thousands of small-cap companies than trading volume. And yet, few aspects are more misunderstood. Here are five critical concepts about trading volume that small-cap officers and directors routinely misunders ...
By David Bautz, PhDNYSE:OGENREAD THE FULL OGEN RESEARCH REPORTBusiness UpdateEnrollment of Phase 2 Trial of AG013 to Complete in 4Q19Oragenics, Inc. (NYSE:OGEN) is currently conducting a Phase 2 clinical trial of its lead development compound AG013 i ...
By Brian Marckx, CFANASDAQ:DRRXREAD THE FULL DRRX RESEARCH REPORTQ2 Financial Results and Operational UpdateDurect Corp (NASDAQ:DRRX) reported financial results for their second quarter ending June 30th and provided a pipeline development update. Maj ...
By David Bautz, PhDTSX:MDNA.TO | OTC:MDNAFREAD THE FULL MDNA.TO RESEARCH REPORTBusiness UpdateMedicenna Therapeutics Corp. (TSX:MDNA) (OTC:MDNAF) is a clinical stage immuno-oncology company developing novel versions of the cytokines Interleukin (IL) ...
By Lisa ThompsonNASDAQ:NETEREAD THE FULL NETE RESEARCH REPORTIn the second quarter of 2019, Net Element (NASDAQ:NETE) beat both our top and bottom line non-GAAP numbers. Total revenues were flat with last year; North American sales increased 9.1% yea ...
By Lisa ThompsonNASDAQ:CSSEREAD THE FULL CSSE RESEARCH REPORTRevenues beat expectations as Crackle turned out contributing more than previously thought despite being part of Chicken Soup for the Soul Entertainment (NASDAQ:CSSE) for only half the quar ...
By Elizabeth Senko, CFAOTC:WIZPREAD THE FULL WIZP RESEARCH REPORTWize Pharma, Inc. (OTC:WIZP) is a clinical-stage company focused on developing an in-licensed product, for the treatment of dry eye syndrome (DES) and related conditions including Sjögr ...
By Lisa ThompsonNYSE:DSSREAD THE FULL DSS RESEARCH REPORTWhile on the surface the second quarter was uninspiring, taking a look at the components of revenue and the outlook for the second half, Document Security Systems, Inc. (NYSE:DSS) is poised for ...
By David Bautz, PhDNASDAQ:CFRXREAD THE FULL CFRX RESEARCH REPORTBusiness UpdateMeeting with the FDA Regarding Exebacase Phase 3 PlanContraFect Corp. (NASDAQ:CFRX) is developing exebacase (CF-301) as the company’s lead lysin product. Lysins are natura ...
By David Bautz, PhDNASDAQ:BCLIREAD THE FULL BCLI RESEARCH REPORTBusiness UpdatePatient Enrollment in Phase 3 ALS Trial to Conclude SoonBrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is continuing to enroll patients in the Phase 3 clinical trial of ...